About the Project

THE CHALLENGE:

Cancer immunotherapies approaches have failed to induce effective immune responses in most patients due to immune evasion mechanisms, including heterogeneity and lack of tumor-antigen presentation. Moreover, these therapies have met limited success in the treatment of solid tumors and are frequently associated with severe adverse effects. RADICAL VISION: The radical vision of the RESYNC consortium is to revolutionize cancer immunotherapy through small-molecule (SM)-based reprogramming of cancer cells into immunogenic (neo)antigen-presenting dendritic cells type 1 (cDC1) to elicit a personalized anti-tumor immunity. The proposed platform will enable breakthrough innovations in the cellular reprogramming-based therapeutics space and have a broad and disruptive effect on the immune-oncology therapeutics scientific field and market.
With a complementary consortium, we expect to achieve proof-of-concept for chemical cDC1 reprogramming by the end of the project (2026).

The RESYNC project received funding from the EIC – European Innovation Council within the framework of “Pathfinder Open” (GA 101130218).